Clicky

Noxopharm Ltd  (NOX)

Description: Noxopharm Limited is a drug development company. The Company is engaged in the research and development of NOX66 in the field of adjuvant therapy in chemotherapy and radiotherapy. The Company focuses on developing a drug to treat cancer. The Company has a primary focus on the development of drugs to treat the problem of drug- and radio-resistance in cancer cells. The Company's drug NOX66 is a dosage formulation developed to protect idronoxil from being inactivated in the human body by Phase II metabolism. Its purpose is to ensure that idronoxil administered remains in an active form. The Company has its offices in Melbourne and Sydney.


Keywords: Medicine Cancer Clinical Medicine Drugs Occupational Safety And Health Oncology Chemotherapy Drug Development Radio Radiation Therapy Radiotherapy Human Body Adjuvant Therapy

Home Page: www.noxopharm.com

NOX Technical Analysis

Tower A, The Zenith
Chatswood, NSW 2067
Australia
Phone: 61 2 9144 2223


Officers

Name Title
Dr. Gisela Mautner CEO, Exec. MD, Chief Medical Officer & Director
Mr. Shawn Van Boheemen Chief Financial Officer
Ms. Jeanette Bell Ph.D. Chief Operating Officer
Dr. John Wilkinson B.Sc., Ph.D. Chief Scientific Officer of Oncology
Dr. Olivier Laczka B.S., M.Sc., Ph.D. Chief Scientific Officer of Inflammation
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. Company Sec.

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.9387
Price-to-Sales TTM: 7.8057
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks